Takeda Pharmaceutical Co Ltd Income Statement

Income Statement Mar2017 Mar2018 Mar2019 Mar2020 Mar2021 Mar2022 Mar2023 Mar2024 Mar2025
Revenue & cost
Revenue 16.02B15.98B18.92B30.28B30.17B31.79B29.81B29.57B30.08B
Cost of Revenue 5.17B4.48B5.88B10.03B9.38B9.86B9.21B9.89B10.37B
Gross Profit 10.85B11.50B13.04B20.25B20.79B21.93B20.60B19.67B19.70B
Operating items
Amortization - Intangibles 1.45B1.10B1.61B4.19B3.98B4.21B4.02B4.52B4.22B
Research & Development 2.89B2.94B3.32B4.53B4.30B4.69B4.69B5.06B4.79B
Selling, General & Administrative 0.13B0.12B0.13B0.15B0.39B0.41B0.45B0.59B0.46B
Operating Expenses 3.02B3.06B3.45B4.68B4.69B5.10B5.13B5.65B5.25B
Operating Income 1.44B2.18B2.14B0.92B4.80B4.10B3.63B1.48B2.25B
EBIT 1.44B2.18B2.14B0.92B4.80B4.10B3.63B1.48B2.25B
Non-operating items
Interest & Investment Income 0.11B0.36B0.15B0.26B1.00B0.21B0.47B0.36B0.31B
Net income details
EBT 1.33B1.96B1.15B-0.56B3.45B2.69B2.78B0.37B1.15B
Tax Provisions 0.26B0.28B-0.07B-0.97B-0.09B0.64B0.43B-0.63B0.44B
Profit After Tax 1.07B1.69B1.22B0.41B3.55B2.05B2.35B1.00B0.71B
Equity Income -0.01B-0.29B-0.39B-0.22B0.00B-0.14B-0.06B0.04B-0.03B
Income from Non-Controlling Interests 0.01B-0.00B-0.00B0.00B0.00B0.00B0.00B0.00B0.00B
Income from Continuing Operations 1.07B1.69B1.22B0.41B3.55B2.05B2.35B1.00B0.71B
Consolidated Net Income 1.07B1.69B1.22B0.41B3.55B2.05B2.35B1.00B0.71B
Income towards Parent Company 1.06B1.69B1.22B0.41B3.55B2.05B2.35B1.00B0.71B
Net Income towards Common Stockholders 1.06B1.69B1.22B0.41B3.55B2.05B2.35B1.00B0.71B
Additional items
EPS (Basic) 1.362.161.270.262.271.311.510.640.45
EPS (Weighted Average and Diluted) 1.352.141.260.262.251.301.490.630.44
Shares Outstanding (Weighted Average) 1.57B1.57B1.56B1.56B1.55B1.57B1.59B
EBITDA 1.44B2.18B2.14B0.92B4.80B4.10B3.63B1.48B2.25B
Interest Expenses 0.22B0.29B0.75B1.52B2.35B1.48B1.26B1.52B1.38B
Tax Rate 19.42%14.04%23.93%15.48%38.23%